Esteban Santos compensation by year
Amgen Summary Compensation Table · all 3 fiscal years held| Component | FY2020 | FY2021 | FY2023 |
|---|---|---|---|
| Salary | $978,446 | $994,246 | $1,061,385 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $2,799,625 | $3,324,824 | $2,939,776 |
| Option awards | $1,199,958 | $1,424,988 | $1,259,986 |
| Non-equity incentive | $1,384,000 | $1,354,000 | $1,688,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $229,624 | $264,575 | $256,689 |
| Total | $6,591,653 | $7,362,633 | $7,205,836 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Amgen Inc. DEF 14A filed April 17, 2024, accession 0001193125-24-099062, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Amgen Inc. filed document, accession 0001193125-24-099062. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 17,068 | $4,915,925 | — |
| PSU | 12,278 | $3,536,310 | — |
| RSU | 11,701 | $3,370,122 | — |
| PSU | 8,987 | $2,588,436 | — |
| Option | 30,100 | — | $235.97 |
| Option | 29,695 | — | $230.92 |
| Option | 9,636 | — | $236.36 |
| Option | 23,062 | — | $239.64 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Amgen Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
29 Form 4 lines since the FY2023 proxy (filed April 17, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-07 | Tax withholding | — | 522 | $331.11 | 82,847 |
| 2026-05-06 | Tax withholding | — | 427 | $329.59 | 83,369 |
| 2026-05-05 | Grant or award derivative | — | 17,814 | $329.59 | 17,814 |
| 2026-05-05 | Grant or award | — | 2,730 | $0.00 | 83,796 |
| 2026-05-02 | Tax withholding | — | 641 | $329.82 | 81,066 |
| 2026-05-02 | Tax withholding | — | 697 | $329.82 | 81,707 |
| 2026-03-16 | Tax withholding | — | 5,621 | $366.21 | 82,404 |
| 2026-03-03 | Grant or award | — | 11,259 | $0.00 | 87,877 |
The 8 most recent of 29 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Amgen discloses, by trigger · FY2023| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $4,269,600 | $13,682,407 | $51,473 | $18,535,440 |
| Retirement | $0 | $13,022,899 | $0 | $13,022,899 |
| Disability | $0 | $13,022,899 | $0 | $13,022,899 |
| Change in control, no termination | $0 | $6,586,153 | $0 | $6,586,153 |
| Death | $0 | $13,022,899 | $0 | $13,022,899 |
Per the Potential Payments Upon Termination or Change in Control table in Amgen Inc.'s FY2023 proxy. Estimates as the company printed them; a dash means it printed no figure.
Amgen’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Robert A. Bradway | Chief Executive Officer and President | $22,643,650 |
| Murdo Gordon | Executive Vice President, Global Commercial Operations | $8,242,811 |
| David M. Reese | Executive Vice President and Chief Technology Officer | $7,902,655 |
| Peter H. Griffith | Executive Vice President and Chief Financial Officer | $7,569,298 |
| Esteban Santos · this page | EVP, Operations | $7,205,836 |
The full Amgen compensation record
free company briefThis page is one person within Amgen's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Amgen proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Amgen's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.